Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial

Neil J Howell, Houman Ashrafian, Nigel E Drury, Aaron M Ranasinghe, Hussain Contractor, Henrik Isackson, Melanie Calvert, Lynne K Williams, Nick Freemantle, David W Quinn, David Green, Michael Frenneaux, Robert S Bonser, Jorge G Mascaro, Timothy R Graham, Stephen J Rooney, Inga Wilson, Domenico Pagano

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Patients undergoing aortic valve replacement for critical aortic stenosis often have significant left ventricular hypertrophy. Left ventricular hypertrophy has been identified as an independent predictor of poor outcome after aortic valve replacement as a result of a combination of maladaptive myocardial changes and inadequate myocardial protection at the time of surgery. Glucose-insulin-potassium (GIK) is a potentially useful adjunct to myocardial protection. This study was designed to evaluate the effects of GIK infusion in patients undergoing aortic valve replacement surgery.
Original languageEnglish
Pages (from-to)170-177
Number of pages8
JournalCirculation
Volume123
Issue number2
DOIs
Publication statusPublished - 2011

Keywords

  • AMP-activated protein kinases
  • acetylglucosamine
  • aged
  • aortic valve
  • aortic valve stenosis
  • cardiac output, low
  • double-blind method
  • female
  • glucose
  • heart valve prosthesis
  • humans
  • hypertrophy, left ventricular
  • incidence
  • insulin
  • male
  • middle aged
  • phosphatidylinositol 3-kinases
  • potassium
  • proto-oncogene proteins c-akt
  • risk factors
  • treatment outcome

Fingerprint Dive into the research topics of 'Glucose-insulin-potassium reduces the incidence of low cardiac output episodes after aortic valve replacement for aortic stenosis in patients with left ventricular hypertrophy: results from the Hypertrophy, Insulin, Glucose, and Electrolytes (HINGE) trial'. Together they form a unique fingerprint.

Cite this